Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Nashville, TN
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Dallas, TX
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Houston, TX
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Hurst, TX
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Hurst, TX
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
San Antonio, TX
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Schertz, TX
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Schertz, TX
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Ogden, UT
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Ogden, UT
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Tacoma, WA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Calgary,
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Status: Enrolling
Updated:  9/6/2017
Ohio State University
mi
from
Columbus, OH
Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Status: Enrolling
Updated: 9/6/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
A Double-blind, Randomized, Single Ascending Dose Escalation, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 Administered to Subjects With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
San Diego, CA
A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
A Double-blind, Randomized, Single Ascending Dose Escalation, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 Administered to Subjects With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Mobile Communication Technology for Adolescents With Diabetes
Adapting Mobile Communication Technology to Improve the Management of Adolescents With Diabetes
Status: Enrolling
Updated:  9/11/2017
Riley Hospital Diabetes Clinics
mi
from
Indianapolis, IN
Mobile Communication Technology for Adolescents With Diabetes
Adapting Mobile Communication Technology to Improve the Management of Adolescents With Diabetes
Status: Enrolling
Updated: 9/11/2017
Riley Hospital Diabetes Clinics
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated:  9/11/2017
GSK Investigational Site
mi
from
Anniston, AL
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated: 9/11/2017
GSK Investigational Site
mi
from
Anniston, AL
Click here to add this to my saved trials
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated:  9/11/2017
GSK Investigational Site
mi
from
Miami, FL
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated: 9/11/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated:  9/11/2017
GSK Investigational Site
mi
from
Miramar, FL
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated: 9/11/2017
GSK Investigational Site
mi
from
Miramar, FL
Click here to add this to my saved trials
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated:  9/11/2017
GSK Investigational Site
mi
from
Nantes cedex 01,
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status: Enrolling
Updated: 9/11/2017
GSK Investigational Site
mi
from
Nantes cedex 01,
Click here to add this to my saved trials
Resilient, Empowered, Active Living: REAL Diabetes Study
Diabetes Self-Management Lifestyle Intervention for Urban Minority Young Adults
Status: Enrolling
Updated:  9/14/2017
USC
mi
from
Los Angeles, CA
Resilient, Empowered, Active Living: REAL Diabetes Study
Diabetes Self-Management Lifestyle Intervention for Urban Minority Young Adults
Status: Enrolling
Updated: 9/14/2017
USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
Status: Enrolling
Updated:  9/14/2017
GSK Investigational Site
mi
from
Chula Vista, CA
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
Status: Enrolling
Updated: 9/14/2017
GSK Investigational Site
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
Status: Enrolling
Updated:  9/14/2017
GSK Investigational Site
mi
from
Miami, FL
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
Status: Enrolling
Updated: 9/14/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  9/18/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 9/18/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  9/18/2017
Gastroenterology Consultants of San Antonio
mi
from
Live Oak, TX
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 9/18/2017
Gastroenterology Consultants of San Antonio
mi
from
Live Oak, TX
Click here to add this to my saved trials
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  9/18/2017
Fundación de Investigación
mi
from
San Juan,
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 9/18/2017
Fundación de Investigación
mi
from
San Juan,
Click here to add this to my saved trials
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated:  9/20/2017
The Regents of the University of California on behalf of its San Diego campus
mi
from
La Jolla, CA
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated: 9/20/2017
The Regents of the University of California on behalf of its San Diego campus
mi
from
La Jolla, CA
Click here to add this to my saved trials
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated:  9/20/2017
AMCR Institute, Inc.
mi
from
San Diego, CA
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated: 9/20/2017
AMCR Institute, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated:  9/20/2017
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated: 9/20/2017
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated:  9/20/2017
Rocky Mountain Diabetes and Osteoporosis Center
mi
from
Idaho Falls, ID
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated: 9/20/2017
Rocky Mountain Diabetes and Osteoporosis Center
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated:  9/20/2017
Kentucky Diabetes Endocrinology Center
mi
from
Lexington, KY
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated: 9/20/2017
Kentucky Diabetes Endocrinology Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated:  9/20/2017
dgd Research, Inc.
mi
from
San Antonio, TX
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
Status: Enrolling
Updated: 9/20/2017
dgd Research, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients
Status: Enrolling
Updated:  9/22/2017
Universtiy of Minnesota
mi
from
Minneapolis, MN
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients
Status: Enrolling
Updated: 9/22/2017
Universtiy of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Computer Based Intervention for Type 2 Diabetes in Youth
Computer Based Intervention for Type 2 Diabetes in Youth: Phase 2
Status: Enrolling
Updated:  9/25/2017
Baylor College of Medicine
mi
from
Houston, TX
Computer Based Intervention for Type 2 Diabetes in Youth
Computer Based Intervention for Type 2 Diabetes in Youth: Phase 2
Status: Enrolling
Updated: 9/25/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
New Horizon Research Center
mi
from
Miami, FL
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
New Horizon Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Suncoast Clinical Research, Inc.
mi
from
New Port Richey, FL
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Suncoast Clinical Research, Inc.
mi
from
New Port Richey, FL
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Atlanta Vanguard Medical Associates
mi
from
Smyrna, GA
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Atlanta Vanguard Medical Associates
mi
from
Smyrna, GA
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Cotton O'Neil Clinic
mi
from
Topeka, KA
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Cotton O'Neil Clinic
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Manhattan Medical Research
mi
from
New York, NY
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Manhattan Medical Research
mi
from
New York, NY
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Aventiv Research
mi
from
Columbus, OH
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Aventiv Research
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
University Diabetes and Endocrine Consultants
mi
from
Chattanooga, TN
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
University Diabetes and Endocrine Consultants
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Dallas Diabetes and Endocrine Center
mi
from
Dallas, TX
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Dallas Diabetes and Endocrine Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Advanced Research Institute
mi
from
South Ogden, UT
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Advanced Research Institute
mi
from
South Ogden, UT
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Tacoma Center for Arthritis Research, PS
mi
from
Tacoma, WA
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Tacoma Center for Arthritis Research, PS
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated:  9/25/2017
Research Site
mi
from
Ahmedabad,
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study
Status: Enrolling
Updated: 9/25/2017
Research Site
mi
from
Ahmedabad,
Click here to add this to my saved trials
Diabetes Prevention Program Outcomes Study
Diabetes Prevention Program Outcomes Study
Status: Enrolling
Updated:  9/25/2017
George Washington University
mi
from
Rockville, MD
Diabetes Prevention Program Outcomes Study
Diabetes Prevention Program Outcomes Study
Status: Enrolling
Updated: 9/25/2017
George Washington University
mi
from
Rockville, MD
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
Anaheim, CA
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
Garden Grove, CA
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
La Jolla, CA
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
Long Beach, CA
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
San Mateo, CA
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
San Mateo, CA
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
Walnut Creek, CA
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated:  9/26/2017
Novo Nordisk Investigational Site
mi
from
Kissimmee, FL
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Status: Enrolling
Updated: 9/26/2017
Novo Nordisk Investigational Site
mi
from
Kissimmee, FL
Click here to add this to my saved trials